These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25539464)

  • 21. High dose rabbit antithymocyte globulin induction in living related liver transplantation.
    Masetti M; Montalti R; Arpinati M; Di Benedetto F; Miller CM; Zagnoli A; De Ruvo N; Guerrini GP; Romano A; Rondelli D; Chirumbolo G; Rompianesi G; Pinna AD; Gerunda GE
    Hepatogastroenterology; 2007; 54(75):884-8. PubMed ID: 17591084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
    Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A
    Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.
    Cuervas-Mons V; Herrero JI; Gomez MA; González-Pinto I; Serrano T; de la Mata M; Fabregat J; Gastaca M; Bilbao I; Varo E; Sánchez-Antolín G; Rodrigo J; Espinosa MD
    Clin Transplant; 2015 Aug; 29(8):667-77. PubMed ID: 25924549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
    Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
    Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.
    Rao V; Haywood S; Abecassis M; Levitsky J
    Transplant Proc; 2013; 45(1):320-2. PubMed ID: 23267806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB
    Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
    Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
    Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients.
    Palanisamy AP; Al Manasra AR; Pilch NA; Dowden JE; Nadig SN; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
    Clin Transplant; 2015 Mar; 29(3):222-6. PubMed ID: 25557762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.